FLUPHENAZINE DECANOATE


Trade Names	FLUPHENAZINE FLUPHENAZINE DECANOATE PROLIXIN DECANOATE
Synonyms	Dapotum d Decazate Fluphenazine decanoate Fluphenazini decanoas Lyogen Modecate Modecate conc Moditen depot NSC-169510 Prolixin decanoate QD-10733 SQ-10733
Status
Molecule Category	UNKNOWN
UNII	FMU62K1L3C
EPA CompTox	DTXSID7023069


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	VIQCGTZFEYDQMR-UHFFFAOYSA-N
Smiles	CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
InChI	InChI=1S/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C32H44F3N3O2S
Molecular Weight	591.78
AlogP	8.0
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	15.0
Polar Surface Area	36.02
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	41.0

Pharmacology

Mechanism of Action	Action	Reference
Dopamine D2 receptor antagonist	ANTAGONIST	PubMed PubMed PubMed Wikipedia


Protein: Dopamine D2 receptor Description: D(2) dopamine receptor Organism : Homo sapiens P14416 ENSG00000149295

Related Entries

--- ---

Cross References

Resources	Reference
ChEBI	5124
ChEMBL	CHEMBL1200854
DrugCentral	1213
FDA SRS	FMU62K1L3C
PubChem	3388
SureChEMBL	SCHEMBL41288
ZINC	ZINC000022816725

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).